Imposing tariffs on the pharmaceutical Trade will considerably influence the earnings of Indian pharma corporations, as almost 40 per cent of India’s whole pharma exports are directed to the US market, in line with a report by SBI Analysis.
The report highlighted that if the US President imposes 50 per cent tariffs on Indian pharma exports as nicely, the earnings of pharmaceutical corporations could decline by 5 to 10 per cent in FY26.
It is because many giant Indian pharma corporations derive between 40 – 50 per cent of their whole income from the US market.
SBI acknowledged “a attainable tariff of fifty per cent on pharma exports could hit earnings of pharma corporations by 5 per cent- 10 per cent in FY26, as many huge pharma corporations’ revenues from US stood within the vary of 40-50 per cent”.
In FY25, round 40 per cent of India’s pharmaceutical exports have been directed to the USA. India’s share within the US’s whole pharma imports stood at 6 per cent in 2024.
A attainable tariff of fifty per cent on pharma exports may also cut back the competitiveness of Indian merchandise on the earth’s largest pharmaceutical market and create stress on revenue margins, as corporations could also be unable to cross on increased prices to customers.
The report famous that India has been a cornerstone of the worldwide provide chain for reasonably priced, high-quality medicines, significantly life-saving oncology medication, antibiotics, and coverings for persistent illnesses.
Within the generic drug market, India provides almost 35 per cent of the US’s pharmaceutical necessities.If the US have been to shift manufacturing and lively pharmaceutical ingredient (API) manufacturing to different nations or home amenities, the transition would take a minimal of three to 5 years to realize significant capability, the report added.
Generic medication account for 90 per cent of prescriptions distributed within the US however signify solely 26 per cent of whole drug spending as of 2018. The report additionally identified that well being expenditure per individual per 12 months within the US is round USD 15,000, and with India’s 35 per cent share in generic drug provides, any tariff is more likely to have a major influence on US residents by growing drugs prices.
